Organization · Venture Capital
Agent Capital
Agent Capital is a healthcare venture capital firm based in Waltham, Massachusetts, focused on investing in novel therapeutics and technologies that address unmet patient needs across various stages of development.
Overview
What Agent Capital does
What Agent Capital is
Agent Capital is a healthcare venture capital firm based in Waltham, Massachusetts, focused on investing in novel therapeutics and technologies that address unmet patient needs across various stages of development.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2017
- Approximate age
- About 9 years
- Structured capabilities
- Funder
- Last reviewed
- April 10, 2026
Official channels
Find Agent Capital elsewhere
Open the official website or a supported primary organization account.
Capability profile
Agent Capital as a funder
Investment thesis
Agent Capital invests in novel, differentiated therapeutics addressing unmet patient needs, emphasizing scientific rigor and clinical validation across all stages of healthcare development.
Focus narrative
Agent Capital specializes in therapeutic areas with high unmet medical needs, including rare diseases, oncology, neurology, and immunology. The firm participates in a wide range of financing rounds, from early-stage investments to later-stage financings, ensuring support throughout the development lifecycle.
Value beyond capital
Agent Capital adds value to its portfolio companies through strong university tech transfer relationships, scientific rigor, and clinical validation. The firm leverages its expertise and network to support the growth and development of innovative healthcare solutions.
Terms and economics
- Typical check
- $1,000,000–$10,000,000
- Sweet spot
- $5,000,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series A+ · Series B · Series B+ · Series C · Series C+ · Series D · Series E · Series F · Growth Equity
- Regions
- North America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 25
- Recorded notable exits
- Dice Therapeutics, ImCheck Therapeutics, and Interius BioTherapeutics
Portfolio context
Notable portfolio companies include: Dice Therapeutics: Oral immunology therapeutics, acquired by Eli Lilly for $2.4B. Freenome: Multiomics platform for early cancer detection via blood tests, going public via SPAC. ImCheck Therapeutics: Immuno-oncology, acquired by Ipsen for EUR 1B. Dragonfly Therapeutics, Carisma Therapeutics, Skyhawk Therapeutics, and others.
Common questions
What to know about Agent Capital
Upseed classifies Agent Capital under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 10, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.